3.2189
Kodiak Sciences Inc stock is traded at $3.2189, with a volume of 8,857.
It is down -3.28% in the last 24 hours and down -31.65% over the past month.
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
See More
Previous Close:
$3.35
Open:
$3.29
24h Volume:
8,857
Relative Volume:
0.02
Market Cap:
$176.29M
Revenue:
-
Net Income/Loss:
$-197.68M
P/E Ratio:
-0.8561
EPS:
-3.76
Net Cash Flow:
$-158.88M
1W Performance:
-6.09%
1M Performance:
-31.65%
6M Performance:
+22.73%
1Y Performance:
-43.94%
Kodiak Sciences Inc Stock (KOD) Company Profile
Name
Kodiak Sciences Inc
Sector
Industry
Phone
650-281-0850
Address
1200 PAGE MILL RD, PALO ALTO, CA
Compare KOD with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
KOD
Kodiak Sciences Inc
|
3.235 | 176.29M | 0 | -197.68M | -158.88M | -3.76 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
513.17 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
669.51 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
618.13 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
259.68 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
267.68 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
Dec-11-23 | Resumed | Goldman | Sell |
Nov-17-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
Jul-27-23 | Downgrade | UBS | Buy → Neutral |
Jul-25-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Jul-25-23 | Downgrade | JP Morgan | Neutral → Underweight |
Jul-24-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
Jul-24-23 | Downgrade | Jefferies | Buy → Hold |
Nov-15-22 | Initiated | CapitalOne | Overweight |
Aug-02-22 | Downgrade | Citigroup | Neutral → Sell |
Feb-24-22 | Downgrade | JP Morgan | Overweight → Neutral |
Feb-11-22 | Initiated | Goldman | Buy |
Feb-02-22 | Upgrade | JP Morgan | Neutral → Overweight |
May-11-21 | Upgrade | ROTH Capital | Neutral → Buy |
Mar-12-21 | Initiated | Evercore ISI | Outperform |
Mar-01-21 | Downgrade | Barclays | Equal Weight → Underweight |
Feb-17-21 | Downgrade | ROTH Capital | Buy → Neutral |
Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Dec-17-20 | Initiated | Berenberg | Buy |
Dec-16-20 | Initiated | UBS | Buy |
Dec-11-20 | Initiated | Citigroup | Neutral |
Nov-30-20 | Downgrade | JP Morgan | Overweight → Neutral |
Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Nov-13-20 | Downgrade | Goldman | Buy → Neutral |
Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
Mar-03-20 | Initiated | Goldman | Buy |
Feb-18-20 | Downgrade | Barclays | Overweight → Equal Weight |
Feb-06-20 | Initiated | SunTrust | Buy |
Jan-08-20 | Initiated | ROTH Capital | Buy |
Jan-03-20 | Initiated | Jefferies | Buy |
Dec-24-19 | Initiated | JP Morgan | Overweight |
Oct-15-19 | Reiterated | Chardan Capital Markets | Buy |
Feb-20-19 | Initiated | Chardan Capital Markets | Buy |
Oct-29-18 | Initiated | Barclays | Overweight |
Oct-29-18 | Initiated | BofA/Merrill | Buy |
Oct-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Kodiak Sciences Inc Stock (KOD) Latest News
Retinal Vein Occlusion Clinical and Non-Clinical Studies, Key - openPR
KOD Completes Enrollment in Phase III Study for Eye Disease Candidate - MSN
Diabetic Retinopathy Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Why Palantir (PLTR) Stock Is Up Today - The Globe and Mail
Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy - Marketscreener.com
Kodiak Sciences completes enrollment in GLOW2 Phase 3 trial - TipRanks
KODKodiak Sciences Inc. Latest Stock News & Market Updates - StockTitan
CDC To Study Vaccines and Autism, Despite Much Research Showing No Link - 69News WFMZ-TV
Clinical Trial Success: Kodiak Enrolls 250+ Patients for Novel Diabetic Eye Drug - StockTitan
Diabetic Retinopathy Pipeline 2025: Mechanism of Action, Route - openPR
We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate - Yahoo Finance
Kodiak Sciences’ Anti-VEGF Could Win Nicely On Retinal Disorders (NASDAQ:KOD) - Seeking Alpha
Kodiak Sciences Inc. (NASDAQ:KOD) Sees Large Increase in Short Interest - MarketBeat
Elisa Oyj (OTCMKTS:ELMUF) Short Interest Update - Defense World
Kodiak Sciences Inc. (NASDAQ:KOD) Sees Significant Growth in Short Interest - Defense World
166,843 Shares in Kodiak Sciences Inc. (NASDAQ:KOD) Bought by Peapod Lane Capital LLC - MarketBeat
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
SG Americas Securities LLC Has $209,000 Stock Holdings in Levi Strauss & Co. (NYSE:LEVI) - American Banking and Market News
SG Americas Securities LLC Has $206,000 Stake in Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Diabetic Retinopathy Market on Track for Major Expansion by 2034, According to DelveInsight | Novartis, Kodiak Sciences Inc., Regenxbio, Perfuse Therapeutics, Hoffmann-La Roche, Boehringer Ingelheim - Barchart
Diabetic Retinopathy Market on Track for Major Expansion - openPR
Quarterly Dosing Breakthrough: Kodiak's New Glaucoma Treatment Targets Root Causes - StockTitan
Kodiak Sciences Inc.'s (NASDAQ:KOD) institutional investors lost 23% over the past week but have profited from longer-term gains - Simply Wall St
JPMorgan Chase & Co. Purchases 30,735 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
NASA's 2 stuck astronauts take their first spacewalk together - 69News WFMZ-TV
Polaris, General Motors And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Age-related Macular Degeneration Treatment Market Size in the 7MM was ~USD 9,840 million in 2023,is further expected to grow by 2034 | DelveInsight - The Globe and Mail
Kodiak Sciences Inc. (NASDAQ:KOD) Shares Purchased by Barclays PLC - Defense World
Gran Tierra Energy Inc. (NYSE:GTE) Shares Bought by Barclays PLC - Defense World
Short Interest in Kodiak Sciences Inc. (NASDAQ:KOD) Rises By 8.1% - Defense World
Contrasting Cidara Therapeutics (NASDAQ:CDTX) and Kodiak Sciences (NASDAQ:KOD) - Defense World
Kodiak Sciences Inc. (NASDAQ:KOD) Short Interest Update - MarketBeat
Jane Street Group LLC Has $90,000 Stock Position in Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Here’s Why Kodiak Sciences Inc. (KOD) Is Skyrocketing - MSN
Why These 24 Stocks Are Skyrocketing - Insider Monkey
KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates - MSN
Diabetic Retinopathy Global Clinical Trials Review 2024: Region, country (G7 & E7), phase, trial status, End-points Status and Sponsor Type - GlobeNewswire Inc.
Geode Capital Management LLC Acquires 12,783 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Kodiak Sciences Inc. (NASDAQ:KOD) Shares Acquired by Barclays PLC - Defense World
Kodiak Sciences CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Crude Oil Surges 2%; Tesla Shares Plummet - Benzinga
Kodiak Sciences (NASDAQ:KOD) Shares Down 2.9%Here's What Happened - MarketBeat
Kodiak Sciences Inc. (NASDAQ:KOD) Shares Purchased by State Street Corp - Defense World
Sanctuary Advisors LLC Reduces Holdings in Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Age-related Vision Dysfunction Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies by DelveInsight - The Globe and Mail
Institutional investors have a lot riding on Kodiak Sciences Inc. (NASDAQ:KOD) with 43% ownership - Yahoo Finance
Kodiak Sciences Inc Stock (KOD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kodiak Sciences Inc Stock (KOD) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
BORGESON JOHN A. | See Remarks |
Jun 12 '24 |
Sale |
2.92 |
1,558 |
4,549 |
179,544 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):